Mortality Risk Pricing

Mortality risk pricing is the valuation problem of estimating when an insured person is likely to die so a life insurance policy can be priced as an investment. You bet your life insurance shows why investors in viatical settlements and life settlements need this estimate: longer survival means more premiums, a delayed death benefit, and lower annualized returns.

The concept is ethically charged because ordinary human longevity becomes the driver of an investment return. It also creates practical uncertainty: new treatments can make estimates wrong, as happened when late-1990s HIV drugs let many people live far longer than viatical investors expected.

Data, Risk, and Actuarial Science in Insurance broadens the concept from policy resale to ordinary Actuarial Science. Mary Pat Campbell explains that life insurance and annuity pricing depend on mortality tables, industry-level data aggregation through the Society of Actuaries, and judgment about whether a shock such as COVID mortality should be projected forward or treated as temporary experience.

Key Claims

• Life-settlement buyers need medical and actuarial estimates to decide how much to bid.
• Longer survival lowers investor returns through both time delay and additional premium payments.
• A policyholder’s illness history can raise bids because it may shorten expected time to payout.
• Medical progress can damage investor assumptions and change the whole market’s target population.
• Portfolio construction reduces dependence on any single person’s exact death date but does not remove mortality-estimation risk.
• Actuarial mortality assumptions must distinguish period shocks from durable future risk; not every bad mortality year should become a new long-term baseline.
• Sparse life-side data can require industry aggregation because individual insurers may not observe enough deaths quickly enough.

Connections

• Life Settlement, Viatical Settlement, and Life Insurance Secondary Market - markets that require mortality estimates.
• Death-Benefit Portfolio - portfolio version of the same risk.
• Frank - seller whose cancer history changes buyer valuation.
• Scott Page - early market builder who sought doctor estimates for investors.
• Investment Risk Management and Portfolio Suitability - broader valuation and risk-control context.
• Actuarial Science, Actuarial Data Quality, Society of Actuaries, and Mary Pat Campbell - actuarial mortality-pricing branch added by Data Science With Sam.